NOSTRAND ROBERT L VAN Insider Trading $ITCI Intra-Cellular Therapies, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for NOSTRAND ROBERT L VAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of NOSTRAND ROBERT L VAN. NOSTRAND ROBERT L VAN is VP, & Chief Financial Officer in OSI PHARMACEUTICALS INC ($OSIP) and Director in METABOLIX, INC. ($MBLX) and in ACHILLION PHARMACEUTICALS INC ($ACHN) and Director in ACHILLION PHARMACEUTICALS INC ($ACHN) and Director in SELLAS Life Sciences Group, Inc. ($GALE) and Director in Enumeral Biomedical Holdings, Inc. ($ENUM) and Director in Intra-Cellular Therapies, Inc. ($ITCI).
NOSTRAND ROBERT L VAN in Intra-Cellular Therapies, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of NOSTRAND ROBERT L VAN: Director
Holdings: 8,273 shares
Current Value: $120,289
Latest Transaction: Apr 02 2021
$ITCI Market Capitalization: $607.92M
$ITCI Previous Close: $14.54
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of NOSTRAND ROBERT L VAN in Intra-Cellular Therapies, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACHN, ENUM, ITCI, OSIP, SLS, MBLX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 02 2021 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 33.93 | 208 | 7,057 | 8,273 | 8.1 K to 8.3 K (+2.58 %) |
| Jul 02 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 25.67 | 275 | 7,059 | 7,567 | 7.3 K to 7.6 K (+3.77 %) |
| May 28 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 22.02 | 20,000 | 440,400 | 20,000 | |
| Apr 02 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 15.37 | 460 | 7,070 | 7,292 | 6.8 K to 7.3 K (+6.73 %) |
| Jan 03 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 34.31 | 170 | 5,833 | 6,832 | 6.7 K to 6.8 K (+2.55 %) |
| Jan 03 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 34.31 | 170 | 5,833 | 6,832 | 6.7 K to 6.8 K (+2.55 %) |
| Oct 02 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 7.47 | 780 | 5,827 | 6,662 | 5.9 K to 6.7 K (+13.26 %) |
| Jul 02 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 12.98 | 449 | 5,828 | 5,882 | 5.4 K to 5.9 K (+8.26 %) |
| Jun 26 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 13.05 | 20,000 | 261,000 | 20,000 | |
| Apr 02 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 12.18 | 478 | 5,822 | 5,433 | 5 K to 5.4 K (+9.65 %) |
| Jan 03 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 11.39 | 512 | 5,832 | 4,955 | 4.4 K to 5 K (+11.52 %) |
| Oct 02 2018 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 21.70 | 268 | 5,816 | 4,443 | 4.2 K to 4.4 K (+6.42 %) |
| Jun 20 2018 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 20.39 | 20,000 | 407,800 | 20,000 | |
| Jun 20 2018 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 20.39 | 20,000 | 407,800 | 20,000 | |
| Oct 03 2017 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 316 | 0 | 3,311 | 3 K to 3.3 K (+10.55 %) |
| Jun 29 2017 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 12.45 | 20,000 | 249,000 | 20,000 | |
| Jan 03 2017 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 331 | 0 | 2,286 | 2 K to 2.3 K (+16.93 %) |
| Oct 04 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 328 | 0 | 1,955 | 1.6 K to 2 K (+20.16 %) |
| Jul 05 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 128 | 0 | 1,627 | 1.5 K to 1.6 K (+8.54 %) |
| Jun 15 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 38.35 | 20,000 | 767,000 | 20,000 | |
| Apr 04 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 134 | 0 | 1,499 | 1.4 K to 1.5 K (+9.82 %) |
| Jan 05 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 53.79 | 69 | 3,712 | 1,365 | 1.3 K to 1.4 K (+5.32 %) |
| Oct 02 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 93 | 0 | 1,296 | 1.2 K to 1.3 K (+7.73 %) |
| Jul 02 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 117 | 0 | 1,203 | 1.1 K to 1.2 K (+10.77 %) |
| Jun 22 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 26.58 | 20,000 | 531,600 | 20,000 | |
| Apr 02 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 157 | 0 | 1,086 | 929 to 1.1 K (+16.90 %) |
Page: 1